Grupp Stephan A, Cohn Susan L, Wall Donna, Reynolds C Patrick
Children's Hospital of Philadelphia, Pennsylvania 19104, USA.
Pediatr Blood Cancer. 2006 Jun;46(7):719-22. doi: 10.1002/pbc.20769.
In this position statement issued by the Hematopoietic Stem Cell Transplant Discipline and the Neuroblastoma Disease Committee of the Children's Oncology Group (COG), we address the feasibility and advisability of collecting sufficient peripheral blood stem cells in neuroblastoma patients to both support the planned initial HDC/SCR procedure(s) as well as allow for therapies, potentially utilized after a recurrence of disease, that may require PBSC support. An additional aliquot of cells for potential subsequent therapies could be collected at the time of the initial PBSC apheresis episode, by any of extending the collection time, extending the apheresis episode by a single day, or cryopreserving a separate aliquot from collections in which large numbers of CD34+ cells are collected.
在儿童肿瘤学组（COG）造血干细胞移植学科和神经母细胞瘤疾病委员会发布的这份立场声明中，我们探讨了在神经母细胞瘤患者中采集足够外周血干细胞的可行性和可取性，以支持计划中的初始大剂量化疗/自体干细胞解救（HDC/SCR）程序，并为疾病复发后可能需要外周血干细胞支持的治疗提供条件。在初始外周血干细胞单采时，可通过延长采集时间、将单采过程延长一天或从采集到大量CD34+细胞的样本中冷冻保存一份单独的样本等方式，额外采集一份细胞用于潜在的后续治疗。
